Health indices closed out the week fairly flat as some stocks benefitted from analyst actions, while others fell because of trial results and lawsuits.
Cadence Pharmaceuticals(CADX Quote) said Friday that in a pivotal late-stage trial its IV-administered Acetavance for pain and fever didn't meet a primary endpoint.
Shares plunged $8.43, or 60.3%, to $5.59 after the company said that in a late stage study its Acetavance for post-operative pain and fever didn't demonstrate a statistically significant reduction in patients' pain over 48 hours compared to placebo after abdominal gynecologic surgery. Acetavance did reduce fever in a separate, smaller study, and was safe and well-tolerated in both studies, according to the company.
The stock tugged at the Nasdaq biotechnology index, which was down 2.99, or 0.35%, at 854.56. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,271.83 | 1,094.60 | 2,191.88 | 35.06 |
Oil *
73.33
|
|
DOWN
36.43
|
DOWN
1.47
|
UP
11.83
|
UP
0.19
|
10 Yr
3.51%
SPDR Gold
108.20
|
|
-0.35%
|
-0.13%
|
+0.54%
|
+0.54%
|
Data delayed 20 minutes |
Connect with TheStreet